These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15534031)

  • 41. Clinical experiences with tolterodine.
    Nilvebrant L
    Life Sci; 2001 Apr; 68(22-23):2549-56. PubMed ID: 11392625
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tolterodine for the treatment of daytime incontinence in children.
    Greenfield SP
    J Urol; 2005 Apr; 173(4):1064. PubMed ID: 15758701
    [No Abstract]   [Full Text] [Related]  

  • 43. Tolterodine for the treatment of overactive bladder: a review.
    Rovner ES
    Expert Opin Pharmacother; 2005 Apr; 6(4):653-66. PubMed ID: 15934891
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modern pharmacotherapy of urge urinary incontinence in the USA: tolterodine and oxybutynin.
    Rovner ES; Wein AJ
    BJU Int; 2000 Oct; 86 Suppl 2():44-53; discussion 53-4. PubMed ID: 11501617
    [No Abstract]   [Full Text] [Related]  

  • 45. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
    Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
    BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tolterodine use for symptoms of overactive bladder.
    Ruscin JM; Morgenstern NE
    Ann Pharmacother; 1999 Oct; 33(10):1073-82. PubMed ID: 10534221
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
    Goepel M
    Urologe A; 2006 Jul; 45(7):847-51. PubMed ID: 16816976
    [No Abstract]   [Full Text] [Related]  

  • 48. PHARMAC responds on tolterodine for overactive bladder.
    Moodie P
    N Z Med J; 2005 Feb; 119(1229):U1871. PubMed ID: 16498471
    [No Abstract]   [Full Text] [Related]  

  • 49. Tolterodine-associated acute mixed liver injury.
    Schlienger RG; Keller MJ; Krähenbühl S
    Ann Pharmacother; 2002 May; 36(5):817-9. PubMed ID: 11978158
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does gender or age affect the efficacy and safety of tolterodine?
    Michel MC; Schneider T; Krege S; Goepel M
    J Urol; 2002 Sep; 168(3):1027-31. PubMed ID: 12187215
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tolterodine: a clinical review.
    Crandall C
    J Womens Health Gend Based Med; 2001 Oct; 10(8):735-43. PubMed ID: 11703885
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Contemporary treatment options for overactive bladder.
    Taylor PH; Sussman DO
    JAAPA; 2005 Nov; Suppl():3-13; quiz 14-5. PubMed ID: 16315503
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.
    Athanasopoulos AA; Perimenis PS
    BJU Int; 2005 May; 95(7):1117-8. PubMed ID: 15839945
    [No Abstract]   [Full Text] [Related]  

  • 54. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group.
    Jonas U; Höfner K; Madersbacher H; Holmdahl TH
    World J Urol; 1997; 15(2):144-51. PubMed ID: 9144906
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability.
    Kilic N; Balkan E; Akgoz S; Sen N; Dogruyol H
    Int J Urol; 2006 Feb; 13(2):105-8. PubMed ID: 16563131
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials.
    Armstrong RB; Dmochowski RR; Sand PK; Macdiarmid S
    Int Urol Nephrol; 2007; 39(4):1069-77. PubMed ID: 17333521
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis.
    Appell RA
    Urology; 1997 Dec; 50(6A Suppl):90-6; discussion 97-9. PubMed ID: 9426760
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Wein AJ
    J Urol; 2005 Jun; 173(6):2056-7. PubMed ID: 15879827
    [No Abstract]   [Full Text] [Related]  

  • 59. Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review.
    Shamliyan T; Wyman JF; Ramakrishnan R; Sainfort F; Kane RL
    Ann Intern Med; 2012 Jun; 156(12):861-74, W301-10. PubMed ID: 22711079
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prominent complaint: a guide to medical therapy of overactive bladder syndrome in older women.
    Jafarabadi M; Ghanbari Z; Hashemi S; Nemati M; Haghollahi F; Azimi Nekoo E
    Acta Med Iran; 2015; 53(2):125-8. PubMed ID: 25725183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.